OncoMed Announces Third Quarter 2017 Financial Results and Operational Highlights
02 nov. 2017 16h05 HE
|
OncoMed Pharmaceuticals, Inc.
Q3 Cash Balance of $113.6M – Cash through Q3 2019 Continued progress on the advancement of key clinical programs including GITRL-Fc Phase 1 initiation Management to Host Conference Call/Webcast this...
OncoMed Doses First Patient with GITRL-Fc in Phase 1a Clinical Trial
13 sept. 2017 08h05 HE
|
OncoMed Pharmaceuticals, Inc.
REDWOOD CITY, Calif., Sept. 13, 2017 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel...
OncoMed Highlights New Data Presented at the American Association for Cancer Research Annual Meeting 2017
05 avr. 2017 08h00 HE
|
OncoMed Pharmaceuticals, Inc.
WASHINGTON and REDWOOD CITY, Calif., April 05, 2017 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing...
OncoMed Presents GITRL-Fc Research at the AACR Annual Meeting 2016
19 avr. 2016 09h00 HE
|
OncoMed Pharmaceuticals, Inc.
REDWOOD CITY, Calif., April 19, 2016 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), presented new data related to its GITRL-Fc immuno-oncology therapeutic candidate at the...
OncoMed to Present Data at the American Association of Cancer Research Annual Meeting 2016
16 mars 2016 16h30 HE
|
OncoMed Pharmaceuticals, Inc.
REDWOOD CITY, Calif., March 16, 2016 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) will present new data related to its clinical and preclinical anti-cancer stem cell and...